Intellectus Partners LLC Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

Intellectus Partners LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 30.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,732 shares of the company's stock after selling 3,905 shares during the period. Intellectus Partners LLC's holdings in Novo Nordisk A/S were worth $616,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Victory Capital Management Inc. raised its holdings in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after purchasing an additional 23,223 shares in the last quarter. Bryn Mawr Capital Management LLC raised its stake in Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. DSM Capital Partners LLC lifted its position in Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after acquiring an additional 286,912 shares during the last quarter. Channing Global Advisors LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at $354,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in Novo Nordisk A/S by 5.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company's stock valued at $5,827,000 after acquiring an additional 3,200 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Stock Up 2.8%

Novo Nordisk A/S stock opened at $74.70 on Friday. The stock has a 50 day moving average of $65.87 and a two-hundred day moving average of $80.71. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The stock has a market capitalization of $335.22 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 0.90 and a beta of 0.66. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.